Introduction: DNA-based TLR9 agonists are potent activators of the immune system. ProMune 1 and dSLIM 1 belong to different families of TLR9 agonists and
Introduction powerful immunological activities [5] [6] [7] [8] [9] . The cellular responses to DNA containing non-methylated CG-motifs are mediated by TLR9 [10] . Although in primates strong stimulation of TLR9 on B lymphocytes (B cells) and plasmacytoid dendritic cells (pDC) can be achieved by using certain ODN in the absence of CG-motifs [11] , all TLR9 agonists hitherto accepted for clinical development contain several CG-motifs. TLR9 is localized to intracellular compartments and detects DNA in the endolysosomal compartment [12] . The host's DNA is regularly not accessible in these compartments, and therefore does not activate TLR9. Exceptions are cellular injuries, leading to the release of nuclear and mitochondrial content to the cytoplasmic compartment or extracellular space, making them accessible for autophagy or cellular re-uptake and subsequent TLR9 binding. Especially, mitochondrial DNA represents an endogenous damage associated molecular pattern molecule [9, 13] as mitochondria evolved from bacteria over endosymbionts to organelles with their DNA still showing certain features of bacterial DNA, like non-methylated CG-motifs.
TLR9 has a rather limited expression profile in humans compared to other TLR, and is exclusively expressed in resting human immune cells by pDC and B cells [2, 14] . Intracellular signaling triggered by TLR9 activation results in up-regulation of two pathways: (1) the activity of the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) is triggered for the production of pro-inflammatory cytokines and acquisition of antigen-presenting functions; and (2) activation of interferon (IFN) regulatory factor 7 (IRF7) leads to type I IFN production [15, 16] . IFN-a is central to link the stimulated innate response to the adaptive arm of the immune system [17] conferring also tumor antigen specific cellular and humoral immune responses.
Due to the unique TLR9 detection profile and the triggered immune responses, TLR9 agonists are currently being tested as adjuvants of antimicrobial, anti-allergic, and especially anticancer immunotherapy. Sequences, early identified by the pioneers in pre-clinical and clinical research on TLR9 agonists Yamamoto, Klinman, Krieg, or Raz [5] [6] [7] [8] , were further developed, and phosphorothioate (PTO) modifications were introduced into molecules. Nucleic acid modification by PTO was supposed to prevent degradation by exonucleases and along other strategies was already in use for antisense therapeutics [18] . The resulting TLR9 agonists were assigned to classes with distinct structural and biological characteristics: A-class CpG-ODN (also known as D-type) [19, 20] , B-class CpG-ODN (also known as K-type) [20, 21] , C-class CpG-ODN [22, 23] , P-class CpG-ODN [24] . A new family of TLR9 agonists is represented by dSLIM 1 [25] , which is a dumbbell-shaped, covalently closed molecule without any PTO modification. For detailed comparison regarding their immunomodulatory properties we have picked the structurally and chemically different TLR9 agonists dSLIM 1 and ProMune
1
. dSLIM 1 is the only TLR9 agonist in clinical development for monotherapy that consists exclusively of natural nucleotides. It has recently successfully finished a double-blinded phase II study in patients with advanced colorectal cancer, exhibiting improved progression-free survival, and durable disease control, compared to placebo [26] . ProMune 1 (B-class) is prominent for being the first TLR9 agonist undergoing human studies and exhibiting exceptional immune activation both in vitro and in vivo [27] . Unfortunately, the in vivo efficacy of ProMune 1 was compromised by a narrow clinical therapeutic window, which finally led to premature closure of advanced oncological trials [28] . The linearly configured ProMune 1 uses PTO-modification in its nucleotides to stabilize the DNA against exonuclease degradation. In mice, these artificial nucleotides and the resulting modified DNA backbone at high concentrations dramatically altered morphology and functionality of lymphoid organs, induced hemophagocytic lymphohistiocytosis, and macrophage activation syndrome [29, 30] . In monkeys, repeated and long-timed application of PTO-ODN resulted in improper complement activation [31] and inhibition of blood coagulation [32, 33] . Here, we dissect the different activation profiles of dSLIM 1 and ProMune 
Materials and Methods
Sequences of TLR9 agonists dSLIM 1 and ProMune 1 as depicted in Figure 1 . dSLIM 
Determination of cytokine concentrations
Secreted cytokines were accumulated in cell growth medium for 2d if not indicated otherwise. ELISA for IFN-a (eBioscience), IFN-g (OptEIA Human IFN-g ELISA Set, BD Biosciences), IP-10, IL-8, and MCP-1 (all from R&D Systems, R&D Systems, Wiesbaden-Nordenstadt, Germany) were performed in duplicates according to the manufacturer's instructions. Optical density was measured at 450 nm; the data were analyzed with the MicroWin software (Berthold Technologies, Bad Wilbad, Germany).
Alternatively, cytokine levels in the cell growth medium were determined in duplicates by a bead-based multiplex immunoassay (FlowCytomix from eBioscience) according to the manufacturer's instructions. Data were acquired on a FACSCalibur and evaluated with the FlowCytomixPro software (eBioscience). The ELISA as well as the multiplex assay for IFN-a were specified to detect IFN-a2a, IFN-a2b, IFN-a2c, but not IFN-a1.
Cytotoxicity assay
Jurkat cells (DSMZ, Braunschweig, Germany) were used as target cells and labeled for 5 min at 378C in RPMI1640 (Lonza) with the lipophilic dye Dil (Invitrogen/Life Technologies, Darmstadt, Germany) at a final concentration of 1 mM. After 18 h, 50,000 target cells were co-cultured with effector cells (treated PBMC) in three different ratios Specif ic cytotoxicity ð%Þ
Statistical analysis The CG-dependent activation of TLR9 negative cells within PBMC by dSLIM 1 is probably mediated by IFN-a.
Co-incubation of dSLIM-activated PBMC with the vaccinia virus protein B18R, that is known to complex type I interferon [36] , abolishes the secretion of IP-10 as well as the activation of monocytes, NK cells, and NKT cells (Fig. 3) . Blocking of type I interferon also impairs the stimulation of PBMC by ODN2216 (see Fig. 3 and others [19] ), a class A CpG-ODN with partial PTO-protection at the termini, known for strong induction of IFN-a, whereas the ProMune 1 effects depicted in Figure 3 are hardly affected.
The relevant immunological effects of dSLIM 1 and Figure 2 . While dSLIM 1 and ProMune 1 both are described as TLR9
agonists and comprise CG-motifs, they clearly differ in molecule parameters (see Fig. 1a ). If separated from its dumbbell-shaped molecule environment in dSLIM 1 and stabilized by PTO, the dissolved loop does no longer generate its genuine activation pattern on immune cells. Over a concentration range from 0.1 to 3 mM DNA, secretion of IP-10 ( Fig. 5b) is abolished. Only a marginal induction of IFN-a secretion is observed at low concentrations of LMLS-PTO (Fig. 5a ). Regarding the efficiency to up-regulate CD86 on monocytes LMLS-PTO ranges between dSLIM 1 and ProMune 1 . Thereby, LMLS-PTO shows the functional footprint of ProMune 1 with a strong secretion of IL-8 ( Fig. 5d ) and heavy activation of B cells (Fig. 5e ) and pDC in terms of HLA-DR up-regulation (Fig. 5f ). This indicates that activation features of ProMune 1 on immune cells can be mimicked by a CpG-ODN with unrelated base sequence and reduced number and different spacing of CG-motifs, if the DNA backbone is completely protected by PTO modifications. With a new set of molecules these new functions of dSLIM-loops in ProMune 1 form, LMLS-PTO, were analyzed for TLR9 specificity. If CG-motifs in LMLS-PTO are mutated into a TLR9 irrelevant GC base sequence, IL-8 secretion (Fig. 5g) and HLA-DR up-regulation on TLR9 positive pDC in PBMC (Fig. 5i ) are unaffected and remain at the same level. Only a partial CG-dependency was detected for the up-regulation of CD86 on B cells (Fig. 5h) . This . Functional parameters of dSLIM 1 or ProMune 1 are displayed as geometric means of the best effect each immunomodulator elicited in several independent assays performed with increasing DNA concentrations (partially used for concentration-effect-curves shown in Fig. 2 ) as well as the specific cytotoxicity at effector:target ratio 10:1 listed in Table 1 . Due to the different ranges of the nine effects displayed, data were medium-corrected and scaled as follows: cytotoxicity À 1 Â specific cytotoxicity; NK cell -1 Â frequency of CD69 upregulation in NK cell population (n ¼ S1 ).
This dominant CG-independent immunoactivation by PTO-ODN increases with the fraction of PTO bonds building the linear ODN as shown for the proportional increase of IL-8 secretion (Fig. 6a) . The different contributions of structure and chemistry in the immunomodulator become evident in IP-10 secretion: the dSLIM 1 dependent IP-10 secretion (Fig. 6b) is greatly reduced if the loop nucleotides are no longer in their dumbbell-shaped structural environment (LMLS). It further diminishes the more genuine phosphodiester-linked nucleotides are replaced by PTO-modified nucleotides in the linear ODN Figure 5 . PTO-modified CpG-ODN and their CG-free variants. PBMC were treated with the TLR9 agonists dSLIM 1 , ProMune 1 , the linearized, fully PTO-modified dSLIM 1 loop (LMLS-PTO), or the appropriate non-CG control ((LMLS-PTO(-CG)) for 48 h at the indicated concentrations. Cytokine levels in the supernatants were determined by ELISA. Cells were stained with antibodies against lineage-and activation markers and analyzed by flow cytometry as described in Materials and Methods section. MFI of activation markers within the cell population are shown. For each parameter, the analyzed effect at the investigated concentrations was normalized to the effect observed at a dSLIM 1 concentration of 3 mM within the test series. Statistical evaluation for the differences between LMLS-PTO and the other molecule was calculated for stimulator concentrations with the most prominent effect in each series using the repeated measures ANOVA with the Fisher's LSD post-test. (a-f): IFN-a n ¼ 6, LMLS-PTO (0.6 mM) versus dSLIM 1 (3 mM) ÃÃÃ , LMLS-PTO (0.6 mM) versus ProMune (Fig. 6c) release: LMLS incubation does no longer induce any detectable IFN-a release from PBMC; partial PTO-modification of the molecule has no further measurable effect. It might be conceivable that the observed inefficacy of LMLS with respect to IFN-a release is the result of a rapid degradation of linear ODN, due to its exonuclease sensitivity. However, the terminal PTO stabilized LMLS molecules do not induce any detectable IFN-a secretion, either. Alternatively, the unprotected LMLS molecule may induce some low-level IFN-a secretion with all molecules already consumed at the time of sample analysis. The latter interpretation is supported by the observed LMLSdependent IP-10 release that may be induced from monocytes by the synergistic action of IFN-a and IFN-g at low concentration [37] . The stabilizing effects of the covalently closed DNA structure in dSLIM 1 and of PTO in linear ODN are demonstrated in Figure 6d during a 1 h-exposure of molecules to the 3 0 -exonuclease activity of T7 DNApolymerase. Under in vitro conditions, optimized for exonuclease activity, LMLS is almost completely degraded within 5 min, while terminal PTO bonds protect the molecule to variable extend: stability of molecules increases (Table S1 ) suggest a reasonable in vivo stability of dSLIM against serum nucleases although these data were not corrected for renal clearance. Corresponding half-times of ProMune 1 are lower [39] .
Transfer of ProMune W into a dSLIM-defined dumbbell structure
While dSLIM
1 loses relevant cancer fighting immunological activities and gains CG-independent effects when it's active loop sequence was converted into a ProMune-like conformation (linearization) and chemistry (PTO modified backbone), we also investigated functional changes of ProMune 1 if adapted to a dSLIM-like conformation (dumbbell) and chemistry (natural backbone). Therefore, we changed part of the dSLIM 1 loop sequences to match the base sequence of ProMune 1 while conserving the dSLIM 1 stem and overall dumbbell conformation. The resulting molecule dSLIM2006-PD (see Fig. S5 ) displays the prevalent dSLIM 1 profile, like high IFN-a, IFN-g, and IP-10 secretion (Fig. 7a) , and efficacious monocyte, NK cell, NKT cell, and T cell activation (Fig. 7b) . In addition, dSLIM2006-PD shows good CD86 induction in B cells. Interestingly, if the loop nucleotides were PTO-modified (dSLIM2006-PTO), relevant dSLIM-specific functions in dSLIM2006 are blunted, while an undesirable trigger to release IL-8 (see Fig. 7a ) shows up. All newly gained effects of dSLIM2006-PD that are missing in dSLIM2006-PTO (e.g., secretion of IFN-a and IP-10 as well as activation of monocytes and NK cells) are strictly dependent on CG-motifs ( 1 is most likely due to the better activation of the IFN-a pathway [17] . This is corroborated by the impaired activation of PBMC to secrete cytokines after blocking of type I interferon (see Fig. 3 ) and the impressive up-regulation of CD169 on monocytes within PBMC by dSLIM 1 [25] . The expression of CD169 on monocytes has recently been shown to be part of a type I IFN response [34, 35] . The mode of action of dSLIM 1 via the induction of the IFN-a-pathway was also strengthened by the in vivo observation of up-regulation of CD169 in peripheral blood monocytes of patients from the IMPACT trial after s.c. application of dSLIM 1 , the active ingredient of Lefitolimod (MGN1703) [26] . Beside the innate immune response, IFN-a also regulates the adaptive arm of antitumor response as was recently shown for the activation of CD8-a þ dendritic cells cross-presenting antigens to cytotoxic T cells [46, 47] . On the other side, ProMune 1 triggers a fivefold higher secretion of IL-8, which rather promotes tumor growth through angiogenesis, and a threefold better maturation of pDC and stronger activation of B cells (indicated by CD86 up-regulation, see that obviously could not be controlled in vivo in the aborted clinical study [28] . Besides other stimuli, IL-8 secretion seems to be triggered by PTO modifications in the commonly used TLR9 agonists. All molecules with substantial portion of PTO nucleotides investigated here did stimulate IL-8 release: ProMune 1 and its corresponding non-CG control (see Fig. S1 ), the single stranded dSLIM-derived loops after conversion into a PTOprotected linear CpG-ODN (LMLS-PTO) (see Fig. 5d ), as well as the CG-motif free variant of LMLS-PTO (see Fig. 5g ). Notably, the IL-8 secretion induced by ProMune 1 as well as by the LMLS-PTO variants is independent from the proposed stimulatory PyNTTTTGT motif [11, 53] . The requirement of PTO modifications for non-CpG ODN to exhibit some stimulating properties has already been observed in different experimental setups [53, 54] with a strong activation of B cells, but a lack to release Th1-relevant cytokines like IFN-a, IFN-g, and IP-10 or to induce a Th2-like immune response in vivo [54] . The PTO effect is corroborated by the positive correlation between evoked IL-8 secretion and the amount of PTO bonds per molecule (see Fig. 6 ). While IL-8 secretion increases with PTO content of stimulator, inverse correlation is observed for IP-10 secretion. Due to their CG-independency, we assume that these off-target effects of PTO-modified ODN are induced at sites different from TLR9, either on TLR9-positive or TLR9-non expressing cells (shown for isolated monocytes in Fig. S7 Fig. 7 ). Apparently, the unique dumbbellshaped conformation of dSLIM 1 is a prerequisite for a stable TLR9-triggered IFN-a release and may be-together with the CG-motifs of the agonist-an additional feature to effectively stimulate the IRF7-signaling branch of TLR9 triggered pathways.
In interesting approaches, IFN-a releasing activity was conferred to class B (or K-type) ODN by multimerization into nanoparticles [55] or more recently by mixing with the HIV-derived peptide Tat (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) to form stable nanorings [56] . Features common to these multimeric structures and dSLIM 1 are several CG-motifs multimerized in a flexible spacing. In contrast to the nanoparticles or nanorings with unknown final composition of the components, the monomeric dSLIM 1 is well defined by three CGmotifs in dimer constellation and devoid of further additives. Additives like nanoparticles or peptides may induce toxicities or unwanted immune responses, and therefore can hamper their clinical application. In contrast, dSLIM 1 molecules (Lefitolimod, MGN1703), exclusively consisting of natural DNA and applied without any additive, showed an excellent safety profile in a recent phase II clinical trial for metastatic colorectal carcinoma [26] . While dimerization may qualify a TLR9 agonist to strongly induce IFN-a secretion in pDC (and subsequently IP-10 release from monocytes), individual base composition, sequence, and/or number of CG-motifs appear to be relevant to activate B cells. The dSLIM 1 and particularly dSLIM2006-PD efficiently combine sequence parameters with structural parameters to form efficient TLR9 agonists with highly efficient anti-tumor activity. Certainly, dSLIM 1 structure does not render every poor immunomodulatory CpG-ODN into a potent anti-cancer vaccine. For instance, the favorable anti-cancer footprint of dSLIM 1 can be masked or even reverted if a non-natural PTO backbone is used to build up this molecule (dSLIM2006-PTO). We cannot distinguish if PTO-modified nucleotides impact the overall dSLIM 1 structure or just change interaction with proteins, including TLR9. However, the pronounced increase of IFN-a induction by PTO-free ODN2216 (see Fig. S4 ) and the complete deficit of fully PTO-modified ODN2216 (ODN2216-PTO) to release any detectable IFN-a argue for the latter scenario. Furthermore, activation of NK cells [57] and secretion of IFN-g [20] in the context of human PBMC require a central phosphorodiester-backbone in the stimulation by TLR9 agonist. Irrespective of the nature of molecular interaction PTO modifications in ProMune 1 mediate considerable off-target-effects that could be avoided if the dumbbell structure of dSLIM 1 is used to protect the ODN from nucleolytic degradation. Even other immunological active sequences than that from ProMune 1 may profit from a dSLIM-like conformation to enhance their efficiency and broaden their functional profile.
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